TME Pharma AG
15
0
1
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer
Role: lead
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
Role: lead
Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer
Role: lead
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Role: lead
First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94
Role: lead
Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients
Role: lead
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Role: lead
Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model
Role: lead
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer
Role: lead
NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers
Role: lead
NOX-A12 First-in-human (FIH) Study
Role: lead
NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria
Role: lead
NOX-E36 First-in-Human (FIH) Study
Role: lead
NOX-E36 Multiple Ascending Dose Study in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus
Role: lead
A Phase I Clinical Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36
Role: lead
All 15 trials loaded